公开(公告)号：US11993647B2

公开(公告)日：2024-05-28

申请号：US16325528

申请日：2017-08-03

Applicant: JOINT STOCK COMPANY “BIOCAD”

Inventor： Stanislav Rudolfovich Evdokimov ,  Andrei Borisovich Ulitin ,  Valery Vladimirovich Solovyev ,  Aleksei Aleksandrovich Aleksandrov ,  Yulia Sergeevna Chernykh ,  Timofey Aleksandrovich Nemankin ,  Anna Konstantinovna Vladimirova ,  Oleg Igorevich Smotrov ,  Tatiana Veniaminovna Chernovskaya ,  Aleksandr Aleksandrovich Moshchenko ,  Viktoriia Evgenevna Nalobina ,  Roman Alekseevich Ivanov ,  Dmitry Valentinovich Morozov

IPC: C07K16/24 ,  A61K9/00 ,  A61K9/19 ,  A61K39/395 ,  A61P37/00 ,  A61P37/06 ,  A61P37/08 ,  C07K16/06 ,  C07K16/18 ,  C12N15/00 ,  C12N15/63

CPC classification number: C07K16/248 ,  A61K9/0073 ,  A61K9/19 ,  A61K39/395 ,  A61P37/00 ,  A61P37/06 ,  A61P37/08 ,  C07K16/065 ,  C07K16/18 ,  C07K16/24 ,  C12N15/00 ,  C12N15/63

Abstract: The invention relates to medicine. The problem addressed by the present invention consists in creating alternative antibodies or fragments thereof which are capable of specifically binding to a human receptor of interleukin-6 and which would be useful as drugs for treating or diagnosing diseases, or for relieving symptoms, mediated by interleukin-6.

公开(公告)号：US11447574B2

公开(公告)日：2022-09-20

申请号：US16564148

申请日：2019-09-09

Applicant: JOINT STOCK COMPANY “BIOCAD”

Inventor： Andrey Borisovich Ulitin ,  Stanislav Rudolfovich Evdokimov ,  Valeriy Vladimirovich Soloviev ,  Yulia Sergeevna Chernykh ,  Olga Vladimirovna Goncharova ,  Dmitriy Valerievich Korzhavin ,  Tatyana Veniaminovna Chernovskaya ,  Timofey Aleksandrovich Nemankin ,  Roman Alexeevich Ivanov ,  Dmitriy Valentinovich Morozov ,  Victoria Mikhailovna Ekimova ,  Ekaterina Vladimirovna Sofronova ,  Yakov Yurevich Ustyugov

IPC: A61K39/395 ,  C07K16/46 ,  A61K45/06 ,  C07K16/24

Abstract: The monoclonal IgG-type antibodies were suggested comprising variable domains represented by a combination of VHH-derivative with a variable domain of the light chain VL. Said antibodies can comprise amino acid substitutions at positions 44 and 45 (Kabat numbering) or combinations thereof. Antibodies of the invention possess increased affinity and improved aggregation stability.

公开(公告)号：US11236167B2

公开(公告)日：2022-02-01

申请号：US16605865

申请日：2018-04-11

Applicant: JOINT STOCK COMPANY “BIOCAD”

Inventor： Andrei Borisovich Ulitin ,  Viktoriia Mikhailovna Ekimova ,  Ekaterina Vladimirovna Sofronova ,  Yulia Sergeevna Chernykh ,  Sergei Andreevich Ageev ,  Anna Konstantinovna Vladimirova ,  Aleksei Aleksandrovich Aleksandrov ,  Pavel Alekseevich Grebnev ,  Valery Vladimirovich Solovyev ,  Iakov Iurevich Ustiugov ,  Pavel Andreevich Iakovlev ,  Timofey Aleksandrovich Nemankin ,  Dmitry Valentinovich Morozov

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06

Abstract: The present invention relates to the field of biotechnology and provides antibodies that specifically binds to PD-L1. The invention also relates to DNA encoding said antibodies, to corresponding expression vectors and to methods of producing, and to methods of treatment using said antibodies.

公开(公告)号：US11136408B2

公开(公告)日：2021-10-05

申请号：US16095800

申请日：2017-07-04

Applicant: JOINT STOCK COMPANY “BIOCAD”

Inventor： Viktoriia Mikhailovna Ekimova ,  Dmitry Valeryevich Korzhavin ,  Yulia Sergeevna Chernykh ,  Timofey Aleksandrovich Nemankin ,  Valery Vladimirovich Solovyev ,  Anna Konstantinovna Vladimirova ,  Irina Andreevna Bulankina ,  Sergei Vasilyevich Diduk ,  Olga Vladimirovna Goncharova ,  Anna Vladimirovna Eroshova ,  Iakov Lurevich Ustiugov ,  Marina Vladimirovna Artiukhova ,  Andrei Borisovich Ulitin ,  Roman Alekseevich Ivanov ,  Dmitry Valentinovich Morozov

IPC: A61K39/00 ,  C07K16/28 ,  C12N15/63 ,  A61K39/395 ,  A61P31/00 ,  A61P35/00

Abstract: The present invention relates to biotechnology and comprises isolated monoclonal antibodies, in particular human monoclonal antibodies, which specifically bind to PD-1 with high affinity. The antibodies according to the invention may be chimeric, humanized or human antibodies, or antigen-binding fragments thereof, and may be used as a medicinal agent in oncology and immuno-oncology, for treating diseases associated with various cell proliferation or development disorders. The invention also relates to methods for producing said antibodies and a method for treating human diseases using said antibodies.